- Q1 2024 Heron Therapeutics Inc Earnings Call TranscriptMay 07, 2024$2.73 (+1.11%)Earnings
- Q4 2023 Heron Therapeutics Inc Earnings Call TranscriptMar 12, 2024$2.44 (-1.81%)Earnings
- Q3 2023 Heron Therapeutics Inc Earnings Call TranscriptNov 14, 2023$0.60182 (+10.93%)Earnings
- Q2 2023 Heron Therapeutics Inc Earnings Call TranscriptAug 14, 2023$1.51 (-10.65%)Earnings
- Q1 2023 Heron Therapeutics Inc Earnings Call TranscriptMay 11, 2023$2.29 (-5.93%)Earnings
- Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 20, 2023
- Q4 2022 Heron Therapeutics Inc Earnings Call TranscriptMar 23, 2023$2.1 (+4.48%)Earnings
- Q3 2022 Heron Therapeutics Inc Earnings Call TranscriptNov 08, 2022$3.42Earnings
- Heron Therapeutics Inc Investor Call TranscriptSep 19, 2022
- Q2 2022 Heron Therapeutics Inc Earnings Call TranscriptAug 09, 2022$4.18 (+18.19%)Earnings
- Q1 2022 Heron Therapeutics Inc Earnings Call TranscriptMay 09, 2022$4.74Earnings
- Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Q4 2021 Heron Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$7.17Earnings
- Heron Therapeutics Inc Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF TranscriptDec 09, 2021
- Q3 2021 Heron Therapeutics Inc Earnings Call TranscriptNov 03, 2021$11.14Earnings
- Heron Therapeutics Inc to Host U.S. FDA Approval of ZYNRELEFâ„¢ - Conference Call TranscriptMay 13, 2021
- Heron Therapeutics Inc 2020 Conference Call TranscriptJun 29, 2020
- Heron Therapeutics Inc Annual Shareholders Meeting TranscriptJun 17, 2020
- Heron Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptOct 02, 2019
- Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 14, 2019
- Heron Therapeutics Inc to discuss the Complete Response Letter - Conference Call TranscriptMay 01, 2019
Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Hi, good morning. Welcome to the 21st Annual Needham Healthcare Conference. I'm Serge Belanger, one of the healthcare analysts at Needham. And we're happy to have for our next session, Heron Therapeutics. We have Barry Quart, the company's CEO; as well as John Poyhonen, the company's Chief Commercial Officer. So, gentlemen, I'll hand it off to you guys. Do you want to start providing I guess an overview of the company and where you are in the launch of ZYNRELEF?
Yeah, definitely happy to do that. Thanks, Serge. I appreciate the opportunity to be here. And so for those that are not familiar with Heron, we have three commercial products. Two of them are in the CINV space, chemotherapy-induced nausea and vomiting, and that we have two products of different mechanisms that are used together potentially or separately, CINVANTI and SUSTOL. And John will be able to give an update in terms of the commercial success of these products, but we have been
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)